Pharmacoscintigraphy · Radiolabelled Drug Evaluation

Visualizing theJourney of MedicinesInside the Human Body

Advanced Pharmacoscintigraphy and Radiolabelled Drug Evaluation for pharmaceutical innovation — turning invisible drug behaviour into decision-grade imaging evidence.

Radiolabelled molecular structure

Live Tracer

99mTc Biodistribution

SPECT-CT
Oral Products
Pulmonary Products
Ocular & Intra-Nasal
Topical & Dermal
Parenteral Products
Specialized & Nano
Oral Products
Pulmonary Products
Ocular & Intra-Nasal
Topical & Dermal
Parenteral Products
Specialized & Nano

Core Services

Six capabilities, one pharmacoscintigraphy technique.

End-to-end radiolabelled drug evaluation, from tracer chemistry to regulatory-ready reports.

All services
01

Radiolabelling

Competence to label most chemical APIs — antibiotics, anti-inflammatories, steroids, receptor-specific drugs, proteins, vaccines, macromolecules and nano-drugs — plus formulations and cells. Pioneers of surface labelling and DPI & MDI labelling at a global level.

02

Pharmaco-Scintigraphy

Human and preclinical gamma scintigraphy — a non-invasive, versatile tool to scrutinise the in-vivo behaviour of your formulations.

03

Clinical Studies

Proof-of-concept, academic and investigator-initiated trials, and Phase 0, I & II studies with full ICH-GCP documentation.

04

Pharmacokinetic Studies

PK data coupled with imaging to reveal time and site of disintegration, GI transit and site-specific drug deposition.

05

Formulation Development

Preformulation, formulation design, QbD and nanotechnology-driven development tailored to your molecule.

06

Analytical & Product Evaluation

Dissolution, dermatokinetics, skin permeation and preclinical safety & efficacy evaluation.

Therapeutic Applications

Every route of administration.

From oral tablets to inhaled aerosols and targeted nanocarriers — we image them all in-vivo.

Oral Products

Dynamic imaging and pharmacokinetic data of formulation movement and dissolution in the human GI tract — from conventional tablets to slow, timed, delayed and colon-release systems, syrups and rectal formulations.

Pulmonary Products

Assessment and optimization of pulmonary drug products — quantifying how formulation, device and patient factors shape lung deposition.

Ocular & Intra-Nasal

Assessment and optimization of ocular and nasal drug products, including nose-to-brain delivery, with specific information on muco-adhesion and residence.

Topical & Dermal

Evaluation of skin deposition, permeation and penetration — including dermatokinetics of NSAIDs, steroids and antiseptics from sprays, ointments, gels and patches.

Parenteral Products

Assessment of IV, IM, IP and SC formulations — biodistribution, pharmacokinetics and relative bioequivalence, plus proof-of-concept for depots, implants and inserts.

Specialized & Nano

Herbal formulations, nutraceuticals and nanoformulations — evaluating in-vivo behaviour, morphology and targeting potential, plus cosmetics, food and less-visited routes.

How It Works

A validated path from protocol to proof.

Seven disciplined stages engineered around your molecule and regulatory pathway.

01

Protocol Design

Bespoke study design aligned to your scientific question and regulatory pathway.

02

Radiolabelling

GMP labelling of the product with a validated, stable radiotracer.

03

Study Execution

Dosing and volunteer management in our clinical imaging facility.

04

Imaging

High-resolution gamma / SPECT-CT acquisition of the drug in-vivo.

05

Image Analysis

Region-of-interest quantification and 3D reconstruction of deposition.

06

PK Analysis

Pharmacokinetic modelling correlating imaging with plasma data.

07

Scientific Report

Regulatory-grade report ready for IND / IMPD submission.

Why Hypotho

The science partner sponsors rely on.

Rigour, speed and regulatory fluency — combined in a single specialised team.

Pioneers in India

The first and only corporate entity providing commercial pharmaco-scintigraphy across India — API, formulation, animal, ex-vivo and in-vitro studies.

Proprietary Labelling

Inventors of surface labelling and DPI & MDI labelling techniques recognised at a global level.

Unmatched Experience

20 years of individual and 100 years of cumulative experience in radiolabelling and scintigraphy clinical trials.

Broad Labelling Competence

Labelling of APIs, biologics, proteins, vaccines, macromolecules, nano-drugs, cells and every major formulation type.

Robust Quality Control

Rigorous, need-based quality control built into every study and radiolabelling batch.

Full Clinical Solution

Expert doctors and coordinators deliver protocol design through to ICH-GCP compliant reports and regulatory submission.

0+

Years Cumulative Experience

0+

Years Individual Expertise

0

Product Categories

0%

In-house Radiolabelling

Start a Conversation

See your molecule in motion.

Partner with our scientists to design an imaging study that answers your most critical development question.